Citadel Advisors
ONCT

Citadel Advisors’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Citadel Advisors’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-535
Closed -$3.69K – 15417
2023
Q2 		$3.69K Buy
535
+80
+18% +$528 ﹤0.01% 13668
2023
Q1 		$7.14K Sell
455
-100
-18% -$1.97K ﹤0.01% 13753
2022
Q4 		$11.1K Sell
555
-135
-20% -$2.69K ﹤0.01% 13589
2022
Q3 		$12K Buy
690
+120
+21% +$2.57K ﹤0.01% 12237
2022
Q2 		$13K Sell
570
-45
-7% -$1K ﹤0.01% 12530
2022
Q1 		$17K Sell
615
-1,295
-68% -$47.1K ﹤0.01% 13293
2021
Q4 		$87K Sell
1,910
-4,595
-71% -$309K ﹤0.01% 12852
2021
Q3 		$543K Buy
6,505
+2,015
+45% +$167K ﹤0.01% 9664
2021
Q2 		$427K Buy
4,490
+2,620
+140% +$311K ﹤0.01% 10411
2021
Q1 		$311K Buy
1,870
+1,130
+153% +$149K ﹤0.01% 10771
2020
Q4 		$73K Buy
+740
New +$46.8K ﹤0.01% 10399
2015
Q4 		– Sell
-2
Closed -$2K – 9330
2015
Q3 		$2K Sell
2
-1
-33% -$1.46K ﹤0.01% 8750
2015
Q2 		$5K Buy
3
+2
+200% +$2.84K ﹤0.01% 8545
2015
Q1 		$1K Sell
1
-1
-50% -$994 ﹤0.01% 8463
2014
Q4 		$2K Buy
+2
New +$1.78K ﹤0.01% 8380
2014
Q3 		– Sell
-2
Closed -$4K – 8488
2014
Q2 		$4K Sell
2
-2
-50% -$3.96K ﹤0.01% 7771
2014
Q1 		$8K Sell
4
-5
-56% -$12.5K ﹤0.01% 7578
2013
Q4 		$20K Buy
9
+1
+13% +$2.29K ﹤0.01% 6461
2013
Q3 		$23K Sell
8
-23
-74% -$114K ﹤0.01% 6153
2013
Q2 		$282K Buy
+31
New +$239K ﹤0.01% 4361

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors's ONCT Position: Q1 2024 in Review

Citadel Advisors sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2024, closing a stake of 2,714 shares — an estimated $29.1K sold.

Citadel Advisors first reported a position in ONCT in Q2 2013 and held it in 21 quarters. The position peaked at $1.29M in Q2 2022. 24 funds tracked by Wall St. Rank hold ONCT as of Q1 2024.

  • Citadel Advisors reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Citadel Advisors sold 2,714 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $29.1K.
  • Citadel Advisors first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 21 quarters.
  • Citadel Advisors's Oncternal Therapeutics, Inc. Common Stock position peaked at $1.29M in Q2 2022.
  • 24 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.